How Much Weight Can You Lose on Ozempic? Real Numbers From Clinical Trials

The Numbers, Up Front

In the largest clinical trial of semaglutide for weight loss (STEP 1), participants lost an average of 14.9% of their body weight — roughly 34 pounds — over 68 weeks on the 2.4 mg dose. About one in three patients lost 20% or more. For a 230-pound person, that's an average drop to around 196 pounds, with top responders reaching 184 pounds or less.

Those are the Wegovy numbers (semaglutide 2.4 mg). Ozempic maxes out at 2 mg and was designed for diabetes, not weight loss, so its weight loss data comes from diabetes trials showing 5-10% loss. But most people searching "Ozempic weight loss" are really asking about semaglutide's full potential — and the data from the STEP program is the most relevant answer.

The newly approved Wegovy HD at 7.2 mg pushes results even higher: 20.7% average weight loss in the STEP UP trial. One-third of patients on the highest dose lost 25% or more of their body weight.

This post breaks down all the clinical trial data, what it looks like month by month, how real-world results compare, and why some people lose dramatically more (or less) than the average.

STEP Trial Results: The Core Data

The STEP (Semaglutide Treatment Effect in People with obesity) program is the most important data set for understanding semaglutide weight loss. It includes multiple large randomized controlled trials testing semaglutide 2.4 mg in different populations. Here's what each one found.

STEP 1: The Flagship Trial

• Population: 1,961 adults with obesity (BMI ≥30) or overweight (BMI ≥27 with at least one weight-related condition), without type 2 diabetes
• Dose: Semaglutide 2.4 mg weekly vs placebo, plus lifestyle intervention
• Duration: 68 weeks
• Average weight loss: 14.9% (semaglutide) vs 2.4% (placebo)
• 5% weight loss achieved: 86.4% of semaglutide patients
• 10% weight loss achieved: 69.1%
• 15% weight loss achieved: 50.5%
• 20% weight loss achieved: ~32%

For a 250-pound starting weight, 14.9% translates to about 37 pounds lost. For 200 pounds, it's roughly 30 pounds. These are averages — the range of individual results was wide, which we'll get into below.

STEP 2: Patients With Type 2 Diabetes

• Average weight loss: 9.6% with semaglutide 2.4 mg vs 3.4% with placebo
• 5% weight loss achieved: 68.8%
• Key takeaway: People with type 2 diabetes consistently lose less weight on semaglutide than those without. This is a biological pattern seen across every GLP-1 trial — insulin resistance and diabetes medications both affect weight loss trajectories.

If you have diabetes and are comparing options, the Mounjaro vs Ozempic comparison includes diabetes-specific data.

STEP 3: Intensive Lifestyle Intervention

• Average weight loss: 16% with semaglutide 2.4 mg vs 5.7% with placebo
• Context: Participants received a structured low-calorie diet for the first 8 weeks, followed by intensive behavioral counseling throughout. The extra lifestyle support added roughly 1 percentage point of weight loss beyond STEP 1.

This trial matters because it shows that combining semaglutide with serious dietary changes does improve outcomes — but the drug is doing most of the heavy lifting. Diet and exercise aren't irrelevant, but semaglutide isn't a "works only if you diet" medication.

STEP 4: What Happens When You Stop

• Design: Everyone started semaglutide for 20 weeks, then half were switched to placebo
• Result: The placebo-switch group regained weight steadily. The group that stayed on semaglutide continued losing through week 68.
• Key takeaway: Semaglutide is not a short-term fix. Stopping the drug reverses the weight loss. The STEP 1 extension data confirmed this — participants who stopped semaglutide regained roughly two-thirds of lost weight within one year.

For a deeper look at what happens after discontinuation, the guide to stopping Ozempic covers the timeline and strategies for maintaining progress.

STEP 5: Two-Year Data

• Average weight loss: 15.2% at 104 weeks (two years)
• Key takeaway: Weight loss was maintained with continued treatment. The 15.2% at two years is nearly identical to the 15.6% measured at one year, meaning the drug holds your weight steady once you reach your new baseline. There's no "tolerance" effect where it stops working.

STEP UP: The Higher Dose (7.2 mg)

• Population: 1,407 adults with obesity, without diabetes
• Doses tested: Semaglutide 7.2 mg vs 2.4 mg vs placebo
• Average weight loss (adherent patients): 20.7% (7.2 mg) vs 17.5% (2.4 mg) vs 2.4% (placebo)
• 25% weight loss achieved: 33.2% (7.2 mg) vs 16.7% (2.4 mg)
• 93.2% of patients on 7.2 mg lost at least 5%

Wegovy HD (7.2 mg) received FDA approval on March 19, 2026, and is expected to launch in April 2026. This dose brings semaglutide's results closer to what tirzepatide achieves in the SURMOUNT trials — and it offers a path forward for patients who've plateaued on 2.4 mg. For dosing details, the semaglutide dosing chart includes the new HD titration schedule.

Oral Semaglutide (OASIS 4)

The oral Wegovy pill (25 mg daily, launched January 2026) showed 16.6% average weight loss in the OASIS 4 trial — comparable to injectable results. If you're considering the pill form, the weight loss potential is similar but delivered without a needle.

Month-by-Month: What to Expect on the Scale

Clinical trial averages are useful, but they don't tell you what week three feels like. Here's how weight loss typically progresses based on STEP trial data and real-world observations. (For a week-by-week breakdown of the full experience, the Ozempic timeline guide goes deeper.)

Month 1 (Weeks 1-4): You're on the 0.25 mg starting dose. This is not a therapeutic dose for weight loss — it exists to acclimate your GI system. Most people lose 0-4 pounds, some of which is water weight from eating smaller portions. Appetite changes may start appearing, but the scale won't move much yet. Side effects like mild nausea are common as your body adjusts.

Month 2 (Weeks 5-8): Dose increases to 0.5 mg. Appetite suppression becomes more noticeable. Food noise — the constant background thoughts about eating — starts quieting down. Weight loss picks up to about 1-2 pounds per week for most people. You've likely lost 4-8 pounds total.

Month 3 (Weeks 9-12): Dose moves to 1 mg. This is where many people start seeing real, visible changes. STEP 1 data shows about 9.6% body weight loss by week 12 for patients on semaglutide. At a 230-pound starting weight, that's roughly 22 pounds. Clothes fit differently. People start noticing.

Months 4-5 (Weeks 13-20): The dose titrates through 1.7 mg up to 2.4 mg (the standard Wegovy maintenance dose). Weight loss continues at a steady rate. Most of the appetite and behavioral changes are well established. GI side effects from dose escalation may flare briefly at each step.

Months 6-9 (Weeks 21-36): You're at your maintenance dose, and this is the steepest part of the weight loss curve for most people. STEP 1 data shows about 13.8% weight loss by month 6. At a 230-pound starting weight, that's around 32 pounds gone. The rate slows slightly as you weigh less (smaller bodies burn fewer calories).

Months 10-16 (Weeks 37-68): Weight loss continues but decelerates. Most patients approach their nadir (lowest weight) around weeks 60-68. The final stretch from month 10 to month 16 might add another 2-4% body weight loss beyond what you'd achieved at month 6.

Beyond Month 16: With continued treatment, weight stays off. STEP 5 showed nearly identical weight loss at one year (15.6%) and two years (15.2%). Without continued treatment, weight regain begins within weeks. This is biology, not willpower — semaglutide is suppressing hormonal signals that return to baseline when the drug is removed.

Want to project your personal timeline? The weight loss calculator estimates month-by-month results based on your starting weight and medication.

Real-World Results vs Clinical Trial Data

Clinical trials are controlled environments. Participants get regular check-ins, structured counseling, and careful dose management. Real life is messier. So how do the numbers hold up outside the trial setting?

A 2026 study published in Obesity tracked 9,916 patients prescribed semaglutide 2.4 mg through a nationwide telehealth platform. Mean weight loss at one year was 14.1% — strikingly close to the 14.9% from STEP 1. Patients who stuck with the medication for the full 68 weeks achieved outcomes "comparable to clinical trial completers."

Another large retrospective study (the SHAPE analysis) found similar patterns: real-world semaglutide users without diabetes lost weight at rates that tracked closely with trial data, provided they remained on the medication.

The gap between trial and real-world results is smaller than many people assume. That said, there's one important caveat: adherence. Clinical trial participants take every dose on schedule. Real-world patients skip doses, pause treatment for cost reasons, or stop entirely. The medication works when you take it. The "average" real-world result includes people who dropped off early — pulling the group average down.

If you're committed to the full treatment course and working with a good provider, STEP trial numbers are a reasonable expectation. Not a guarantee, but a grounded estimate.

Super Responders, Average Responders, and Non-Responders

The 14.9% average from STEP 1 is just that — an average. Individual responses vary enormously, and understanding this distribution is more useful than fixating on the mean.

Super responders (32-40% of patients): Lost 20% or more of their body weight. At the extreme end, some patients in STEP trials lost 30%+. These individuals tend to experience strong appetite suppression early, tolerate dose escalation well, and often combine the medication with meaningful changes to diet and activity.

Average responders (~40-50% of patients): Lost between 10-20% of body weight. This is where most people land. The medication clearly works — appetite is reduced, portions shrink, weight comes down steadily — but the results don't make headlines.

Low or non-responders (10-17% of patients): Lost less than 5% of body weight. Some people simply don't respond strongly to GLP-1 receptor agonists. The reasons aren't fully understood, but genetics, metabolic state, and possibly gut microbiome differences all play a role.

A few patterns emerge in who responds best versus least:

• Gender: Women tend to lose more weight on semaglutide than men. Real-world data shows 14-16% average loss for women vs 8-9% for men. The reason isn't clear, but hormonal and metabolic differences likely factor in.
• Diabetes status: People with type 2 diabetes consistently lose less (STEP 2 showed 9.6% vs STEP 1's 14.9%). Insulin resistance, diabetes medications, and metabolic adaptations all blunt the weight loss effect.
• Starting BMI: People with higher BMIs often lose a larger absolute amount of weight but a similar or slightly lower percentage of body weight compared to those with moderate obesity.
• Early response: Patients who lose at least 5% in the first 12 weeks tend to be on a strong trajectory. But STEP 4 data showed that even slow early responders can achieve meaningful results by sticking with the full titration.

If you're two months in and the scale isn't moving much, don't panic. But do talk to your provider. A dose adjustment, medication switch, or lifestyle change might be in order. For people who are considering tirzepatide as an alternative, it does produce higher average weight loss (20.2% in the SURMOUNT-5 head-to-head trial) and might be worth discussing.

Semaglutide vs Tirzepatide: The Weight Loss Comparison

People asking "how much weight will I lose on Ozempic?" often want to know how it stacks up against the competition. Here's the direct comparison.

The SURMOUNT-5 trial (published May 2025, NEJM) randomized 751 adults to either maximum-dose tirzepatide or maximum-dose semaglutide for 72 weeks. The results:

	Semaglutide (2.4 mg)	Tirzepatide (15 mg)
Mean weight loss	13.7%	20.2%
Mean pounds lost	33.1 lbs	50.3 lbs
Achieved ≥20% loss	26.6%	53.3%
Achieved ≥25% loss	16.1%	31.6%

Tirzepatide wins on raw numbers. That's consistent across every study. But semaglutide at the new 7.2 mg dose (20.7% in STEP UP) narrows the gap significantly. There's no head-to-head trial comparing Wegovy HD to tirzepatide yet.

Both drugs work. If your insurance covers one but not the other, or if side effect tolerance pushes you toward a specific medication, the "lesser" option still produces life-changing weight loss for most people. The Mounjaro vs Ozempic comparison breaks this down in brand-name terms, and the GLP-1 overview explains the mechanism differences.

What a Weight Loss Plateau Looks Like (and What to Do)

Nearly everyone on semaglutide hits a plateau. STEP trial data shows weight loss reaching its lowest point around week 60. After that, the drug isn't "stopping" — it's maintaining. Your body has found a new equilibrium where the reduced appetite from semaglutide matches your body's lower calorie needs at the new weight.

Common reasons for earlier-than-expected stalls:

• Metabolic adaptation: As you lose weight, your body burns fewer calories at rest. The deficit that produced weight loss at 230 pounds may not produce a deficit at 200 pounds unless you adjust food intake or activity.
• Lean mass loss: Up to 39% of weight lost on semaglutide can come from lean muscle, not fat. Less muscle means lower resting metabolism. Resistance training and adequate protein intake (at least 0.7g per pound of target body weight) help preserve muscle and keep metabolism up. The GLP-1 muscle loss guide covers this in detail.
• Calorie creep: Appetite suppression from semaglutide can wane slightly over time as your body adapts. Portions gradually increase without you noticing. A food journal for a week or two can reveal patterns.
• Dose room: If you're on Ozempic at 2 mg, you're below the dose ceiling that was tested for weight loss. Switching to Wegovy and titrating to 2.4 mg — or eventually to 7.2 mg with Wegovy HD — may restart progress. Your provider can evaluate this option using a framework like the dose titration calculator.

What to try before making medication changes:

• Add strength training 2-3 times per week if you haven't already
• Increase protein to at least 100g daily
• Review your diet on semaglutide — certain foods exacerbate GI side effects and may cause you to avoid eating things that support satiety and metabolism
• Cut back on alcohol, which adds empty calories and interferes with semaglutide's metabolic benefits
• Talk to your provider about a dose increase or medication switch

Plateaus are normal, expected, and not a sign that the drug has failed. They're a sign that your body has adapted. The question is whether there's still room to adjust.

Looking Ahead: What Else Is Coming

Semaglutide's weight loss story isn't finished. Beyond Wegovy HD, there are newer compounds in late-stage development:

• Retatrutide: A triple agonist (GLP-1, GIP, and glucagon receptors) that showed 24.2% average weight loss in Phase 2 trials. Phase 3 data is expected in 2026-2027.
• Oral tirzepatide: Eli Lilly is developing a pill version of tirzepatide (the drug in Mounjaro and Zepbound), which could reshape the oral weight loss medication space.
• Amycretin: Novo Nordisk's next-generation dual amylin and GLP-1 agonist showed 22% weight loss at just 36 weeks in a Phase 2 study — suggesting it may surpass semaglutide at any dose.

The field is moving fast. Today's numbers are already better than what was available two years ago, and the next generation of treatments will push them further.

Getting Started

If the data in this post has you considering semaglutide, the first step is a conversation with a licensed provider. They'll evaluate whether you're a candidate based on your BMI, medical history, current medications, and goals. They'll also help you figure out the insurance and cost situation before you commit.

Not sure where to start? Take the provider-matching quiz to connect with a licensed prescriber who can walk you through your options — whether that's Ozempic, Wegovy, the new oral pill, or a different GLP-1 entirely.

If cost is the main barrier, explore the GLP-1 cost calculator to compare pricing across formulations and see what savings programs you might qualify for. The telehealth semaglutide guide also covers lower-cost access through online providers.

Frequently Asked Questions About Ozempic Weight Loss Results

What is the average weight loss on Ozempic in 3 months?

In the STEP 1 trial, participants on semaglutide 2.4 mg lost an average of 9.6% of their body weight by week 12 (about 3 months). For a person starting at 230 pounds, that's roughly 22 pounds. Keep in mind that the first 4-5 weeks involve low-dose titration where weight loss is minimal — most of the 3-month result comes from weeks 5-12 as the dose ramps up. Ozempic's dosing schedule walks through each titration step. At the standard Ozempic dose of 1 mg (lower than the 2.4 mg used in STEP trials), weight loss at 3 months is typically closer to 5-7%.

How much weight do you lose on Ozempic in 6 months?

STEP 1 trial data shows approximately 13.8% body weight loss at 6 months (24 weeks) on semaglutide 2.4 mg. For someone starting at 250 pounds, that translates to about 34 pounds. Most patients are at or near their full maintenance dose by this point, and weight loss is occurring at a steady 1-2 pounds per week. Six months is roughly the halfway point to maximum results. Your individual pace depends on starting weight, dose, diet, and activity level. The weight loss calculator can generate a personalized estimate.

Why am I not losing weight on Ozempic?

Several factors can blunt semaglutide's weight loss effect. The most common: you haven't reached a therapeutic dose yet (the 0.25 mg and 0.5 mg starting doses don't produce much weight loss), calorie intake is still exceeding your deficit despite reduced appetite, or you have metabolic factors like type 2 diabetes or insulin resistance that dampen the response. About 10-17% of patients in clinical trials lost less than 5% of body weight — some people simply respond less to GLP-1 agonists. If you've been on a stable dose for 8+ weeks with minimal results, discuss a dose increase, medication switch, or metabolic workup with your provider. The how long does Ozempic take to work guide has a troubleshooting section.

Do you regain weight after stopping Ozempic?

Yes, on average. The STEP 1 extension study found that participants who stopped semaglutide regained about two-thirds of their lost weight within one year. This isn't a flaw in the drug — it's the expected biological outcome when you remove a hormone that was suppressing appetite and altering metabolism. Most providers treat semaglutide as an ongoing medication, similar to blood pressure drugs. Some patients taper to a lower maintenance dose rather than stopping entirely. The guide to stopping Ozempic covers the timeline and strategies in detail.

Is Ozempic or Mounjaro better for weight loss?

On raw numbers, tirzepatide (Mounjaro/Zepbound) produces more weight loss than semaglutide (Ozempic/Wegovy). The SURMOUNT-5 head-to-head trial showed 20.2% weight loss for tirzepatide vs 13.7% for semaglutide at 72 weeks. The new semaglutide 7.2 mg dose (Wegovy HD) closes this gap somewhat at 20.7%. Both are effective, and the "better" choice depends on your insurance, tolerance of side effects, and provider's experience. The Mounjaro vs Ozempic comparison and the semaglutide vs tirzepatide breakdown both cover this in detail.

Does starting BMI affect how much weight you lose on Ozempic?

People with higher starting BMIs tend to lose more weight in absolute terms (more total pounds) but a similar or slightly lower percentage of body weight compared to those with moderate obesity. In STEP trials, the average percentage loss was consistent across BMI categories, though individual variation was large. Factors like diabetes status, age, gender, and genetics had a bigger influence on response than starting BMI alone. Women lost more on average (14-16%) than men (8-9%) in real-world data.

Can I take Ozempic just for a few months to lose weight and then stop?

You can, but the data strongly suggests the weight will come back. Semaglutide works by continuously suppressing appetite signals and altering metabolic pathways. When you stop, those signals return to baseline. STEP 4 showed that patients switched to placebo after 20 weeks of semaglutide immediately began regaining weight. If you're looking for a temporary intervention followed by maintenance through lifestyle alone, discuss realistic expectations with your provider. Some patients use semaglutide to reach a target weight and then transition to a lower maintenance dose rather than stopping completely.

How do Ozempic weight loss results compare to surgery?

Bariatric surgery (gastric sleeve or bypass) typically produces 25-35% body weight loss — more than semaglutide at standard doses. However, Wegovy HD at 7.2 mg (20.7%) is closing the gap, and the next generation of triple agonists like retatrutide may narrow it further. Surgery is a one-time procedure with permanent anatomical changes. Semaglutide requires ongoing treatment. The right comparison depends on your BMI, health conditions, surgical risk tolerance, and access. If you're exploring options, talk to a provider who can discuss both medical and surgical approaches based on your specific situation.